Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $10.80 Average PT from Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been given a consensus rating of “Hold” by the seven research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $10.80.

A number of research firms have recently weighed in on XERS. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a report on Monday, March 2nd.

Xeris Biopharma Stock Performance

XERS opened at $6.95 on Friday. The business’s 50 day moving average is $6.29 and its 200-day moving average is $6.57. The stock has a market cap of $1.20 billion, a PE ratio of 115.83 and a beta of 0.78. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. Xeris Biopharma has a twelve month low of $4.40 and a twelve month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The company had revenue of $83.13 million for the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, analysts predict that Xeris Biopharma will post 0.12 earnings per share for the current year.

Insider Activity

In related news, Director John Johnson sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $91,350.00. Following the sale, the director owned 683,083 shares of the company’s stock, valued at $4,159,975.47. The trade was a 2.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Marla Persky sold 15,500 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $5.90, for a total value of $91,450.00. Following the sale, the director directly owned 126,500 shares in the company, valued at approximately $746,350. The trade was a 10.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 127,335 shares of company stock valued at $766,733 over the last 90 days. Corporate insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma during the fourth quarter worth approximately $25,000. KBC Group NV acquired a new position in Xeris Biopharma in the first quarter worth approximately $27,000. AlphaQuest LLC acquired a new position in Xeris Biopharma in the third quarter worth approximately $35,000. Caitong International Asset Management Co. Ltd grew its position in Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after buying an additional 7,421 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.